In the TIMER database, in the absence of tumor purity, the expression level of SH2D1A was significantly correlated with the expression of the immune cell markers PDCD1, MS4A4A, HLA-DRA, KIR2DL4, CD8A, CD3E, CD79A, CD86, STAT6, CSF1R, CCL2, CD68, IL10, IRF5, PTGS2, IL17A, CD163, VSIG4, CD8B, CCR7, HLA-DQB1, KIR2DL1, KIR2DL3, KIR3DL2, KIR3DL1, HLA-DPA1, CD19, CD1C, NRP1, CD3D, ITGAX, TBX21, HLA-DPB1, STAT4, STAT1, IFNG, TNF, KIR3DL3, GATA3, STAT5A, IL13, CD2, IL21, STAT3, FOXP3, ITGAM, CCR8, TGFB1, CTLA4, LAG3, KIR2DS4, HAVCR2, and GZMB (Table 2). The gene discussed is IRF5; the disease is neoplasm.